Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
暂无分享,去创建一个
R. Krance | H. Heslop | C. Rooney | C. Bollard | U. Popat | A. Gee | M. Brenner | D. Przepiorka | B. Grilley | I. Kuehnle | B. Gahn | G. Carrum | M. Gresik | S. Khan